On Tuesday, Iterum Therapeutics Plc (NASDAQ: ITRM) opened higher 6.47% from the last session, before settling in for the closing price of $1.39. Price fluctuations for ITRM have ranged from $0.71 to $2.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -39.15%. Company’s average yearly earnings per share was noted 68.93% at the time writing. With a float of $21.95 million, this company’s outstanding shares have now reached $22.71 million.
Let’s determine the extent of company efficiency that accounts for 14 employees. In terms of profitability, gross margin is 65.99%, operating margin of -1460.11%, and the pretax margin is -1066.98%.
Iterum Therapeutics Plc (ITRM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Iterum Therapeutics Plc is 3.33%, while institutional ownership is 1.47%. The most recent insider transaction that took place on Dec 22 ’23, was worth 35,000. In this transaction Director of this company bought 25,000 shares at a rate of $1.40, taking the stock ownership to the 113,754 shares. Before that another transaction happened on Dec 18 ’23, when Company’s Director bought 10,000 for $1.84, making the entire transaction worth $18,442. This insider now owns 88,754 shares in total.
Iterum Therapeutics Plc (ITRM) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.3 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.91) by 0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.93% per share during the next fiscal year.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Check out the current performance indicators for Iterum Therapeutics Plc (ITRM). In the past quarter, the stock posted a quick ratio of 0.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Looking closely at Iterum Therapeutics Plc (NASDAQ: ITRM), its last 5-days average volume was 1.11 million, which is a jump from its year-to-date volume of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 78.06%. Additionally, its Average True Range was 0.16.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 44.44%, which indicates a significant increase from 31.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 254.12% in the past 14 days, which was higher than the 119.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1384, while its 200-day Moving Average is $1.3349. However, in the short run, Iterum Therapeutics Plc’s stock first resistance to watch stands at $1.5500. Second resistance stands at $1.6200. The third major resistance level sits at $1.7200. If the price goes on to break the first support level at $1.3800, it is likely to go to the next support level at $1.2800. Now, if the price goes above the second support level, the third support stands at $1.2100.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
There are currently 22,706K shares outstanding in the company with a market cap of 33.60 million. Presently, the company’s annual sales total 0 K according to its annual income of -38,370 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -5,000 K.
